rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KPRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
      Nov 12Yahoo FinanceKPRX
      Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan
      Oct 29Yahoo FinanceKPRX
      Kiora Pharmaceuticals Bolsters Leadership in Clinical Development

      Detailed price information for Kiora Pharmaceuticals Inc. (KPRX-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailKPRX
      Kiora Pharmaceuticals names Keith Lane clinical development head
      Sep 8Investing.comKPRX
      Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

      Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora's pipeline and new asset opportunitiesEncinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience

      Sep 8Yahoo FinanceKPRX

      This is the newest page. Registered accounts read further back.